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Abstract 
According to the American Cancer Institute, in 2018, cancer had an estimated 1,735,350 
new cases and 609,640 people will die in the United States alone. Like many deadly diseases, 
cancer has found ways to evade the immune system. Many cancers were recently shown to 
overexpress CD47, a widely expressed “don’t eat me” signal, which interacts with the immune 
cells’ signal receptor protein alpha (SIRPα), to prevent programmed cell removal (PCR) 
(Oldenborg et al., 2001). Recent advances have been made to target the CD47-SIRPα pathway to 
prevent the antiphagocytic activity seen in many cancers. The scope of this review is limited to 
two new methods used to inhibit the CD47-SIRPα pathway: anti-CD47 and SIRPα antibodies, 
and small peptide inhibitors. The antibodies for CD47 have shown effectiveness in clinical trials. 
Antibody inhibition for CD47 and SIRPα were compared, and SIRPα produced better cell type 
specific inhibition, but similar on-target healthy cell phagocytosis caused anemia in both trials. 
Several factors, including degradation and inability to penetrate dense tumors, hinder antibody 
treatment in all cancer patients; therefore, small peptide inhibitors offer an alternate route for 
inhibition to occur.  
 
Introduction 
PCR is an efficient and accurate process that clears dead, dying, or infectious cells. 
Phagocytic macrophages​—​neutrophils, dendritic cells and monocyte derivatives​—​perform PCR, 
and acts independently of apoptosis, thereby, preventing pro-inflammatory molecules from being 
released (Lagasse and Weissman, 1994; Choa et al. 2011). Cells that are under oxidative stress 
release chemotactic factors that attract immune cells (Choa et al., 2011). Once the macrophage 
locates the infected cell, it recognizes the cell through “don’t eat me” or, “eat me” ligands to 
prevent or induce cell engulfment, respectively. The scope of this review is limited to a signal 
ligand​—​receptor interaction between cluster of differentiation 47 (CD47)​—​a widely expressed 
transmembrane protein (Brown and Frazier, 2001)​—​and signal receptor protein alpha 
(SIRPα)​—​a receptor expressed on phagocytic immune cells. CD47 links to SIRPα and acts as a 
“don’t eat me” signal to prevent cellular phagocytosis. 
Macrophages activate specific transcription factors in response to environmental cues. 
Notch signaling describes the macrophages’ internal protein cascade upon receptor-ligand 
interactions. The macrophage responds by adjusting its polarization into either phagocytic, 
categorized as the M1 polarization, or non-phagocytic (M2) (Alvey and Discher, 2017). This is 
important because a macrophages’ phenotype is environmentally dependent and plays a critical 
role in PCR. For example, upon binding CD47, SIRPα initiates an inhibitory signal transduction 
cascade via src homology-2 domain recruitment that contains the protein tyrosine phosphatases 
 SHP-1 and SHP-2. Once activated, SHP-1 propagates a downstream antiphagocytic signal (M2) 
through an unknown mechanism (Barclay and Brown, 2006; Oldenborg et al., 2001; Lin et al., 
2018). Naturally, this ensures macrophages do not engulf healthy cells. In fact, a single 
CD47-SIRPα interaction is capable of preventing phagocytosis (Ho et al., 2015).  
One mechanism cancer uses to evade the immune system is through the CD47-SIRPα 
pathway. For cancer to propagate it must: prevent apoptosis, divide rapidly and evade the 
immune system (Ottaviano et al., 2019). Many cancers overexpress CD47 and, it is hypothesized 
that CD47 accumulation acts as a camouflage. Therefore, inhibiting the CD47-SIRPα pathway is 
a favorable route for therapeutics (Oldenborg et al., 2001). Efforts have been made to target 
CD47 and SIRPα individually through monoclonal antibodies (mAb) and high-affinity small 
peptides. These methods, coupled with known cancer therapeutics, have been shown to decrease 
tumor cell density in vitro, in vivo, and in clinical trials. The main goal here is to assess the 
potential adverse effects presented in each therapeutic. Major hurdles i​nclude the potential for 
other phagocytic inhibitors​, off-target effects, and the lack of long-term effects. 
 
Antibody targeting of CD47 and SIRPα​ ​shows inhibition of anti-phagocytic signaling 
Antibody targeting of CD47 is an effective therapeutic for specific cancers. Acute 
myelogenous leukemia (AML) is maintained by self-renewing leukemia stem cells (LSC) which 
evade phagocytosis through increased CD47 expression (Chao et al., 2011; Oldenborg et al., 
2001). By targeting CD47, researchers hope to activate a focused immune response against 
tumor cells. Both, in vitro and in vivo analysis of an anti-CD47 antibody (B6H12.2) in an AML 
LSC model reported a 3-5 fold increase in phagocytosis compared to macrophages and tumor 
cells alone (Majeti et al., 2009). In contrast, an anti-SIRPα antibody reported an increased 
phagocytosis only when coupled with trastuzumab​—​a known breast cancer therapeutic (Zhao et 
al., 2011). This contradiction is important, firstly, because it shows antibodies alone are 
insufficient to increase phagocytosis. Secondly, it hypothesizes other “don’t eat me” signals 
continue to inhibit phagocytosis after the CD47-SIRPα has been blocked. Lastly, it shows two 
alternate ways to inhibit the CD47-SIRPα pathway. The anti-SIRPα antibody is argued as a 
favored cancer therapeutic because CD47 is widely expressed across cell types. Targeting CD47 
may cause unwanted on-target CD47 phagocytosis. Despite this possibility, an i​n vivo​ analysis of 
B6H12.2 reported no additional phagocytic activity even with equivalently coated cells (Chao et 
al., 2011). However, therapeutic exposure only lasted 14 days and animal models were sacrificed 
afterwards; therefore, long term effects have not been assessed. 
 
Anti-CD47 antibody development towards human variant 
A limitation to antibody therapeutics is inter-species variation. B6H12.2s’ affinity 
decreased from mice to humans due to CD47 variation. Therefore, a human anti-CD47 antibody 
(5F9) was produced and grafted to immunoglobulin G4 scaffold (IgG4) (Liu et al., 2015). The 
resulting antibody (Hu5F9-G4) was tested in vitro for its affinity towards human CD47 and 
 revealed strong attraction (K​D​= 1x10​-12​). Hu5F9-G4 was further tested in cynomolgus monkeys 
to assess potential toxicity in a human-like model. No serious adverse events were characterized 
except dose dependent anemia which, was expected and reverted naturally after antibody 
treatment (Oldenborg et al., 2001).  However, using healthy monkeys was a limitation to this 
study; tumor cell phagocytosis was not assessed in vivo. Furthermore, the toxic effects were only 
tested in a three week period and no long-term effects were characterized.  
 
Clinical trials for the human CD47 antibody variant 
Clinical trials of Hu5F9-G4 antibody coupled with rituximab are currently being 
conducted. Toxicity and effectiveness were assessed in 22 patients with aggressive and indolent 
lymphoma (Advani et al., 2018). From this sample, 50% had an objective response and 36% had 
a complete response. Furthermore, by day 28, white and red blood cells had, an approximate, 
100% of their CD47 receptors occupied. This is important because blocking all CD47-SIRPα 
interactions is needed for effective results (Ho et al., 2015) and, since all cells are not degraded, 
other signals must be preventing phagocytosis on healthy cells. As seen in other animal models, 
dose-dependent anemia was the most common side-effect but, it reverted to baseline at lower 
dosages or after the treatment period (Oldenborg et al., 2001). This coupled treatment showed 
promising results for patients with aggressive and indolent lymphoma. 
 
High-affinity small peptides as an alternate CD47-SIRPα inhibitor 
Another issue with antibody therapeutics is their poor permeability into dense tumors 
(Chames et al., 2009). Given this hurdle, an alternate route is small peptide inhibitors against the 
CD47-SIRPα pathway. By antagonizing CD47 or SIRPα, the small peptides should block any 
anti-phagocytic signaling and allow PCR to occur. Small peptides are highly specific antagonists 
modeled after invariable regions of their target. By analyzing the human SIRPαs’ binding 
domain, a competitive antagonist for human CD47 was produced (Weiskopf et al., 2013). The 
high-affinity SIRPα monomer (CV1) was tested in vitro to assess its affinity towards human and 
mouse CD47. CV1 presented the same inhibition between human and mouse CD47 variants 
(50,000-fold affinity increase and K​D​=34.0 pm). Since small peptides are modeled after 
invariable regions, their affinities are similar between species. This is important because affinity 
testing for humans can now be estimated through animal models; thereby, eliminating toxic and 
costly human trials. Furthermore, ex vivo co-treatment of CV1 with anti-Her2/neu​—​a well 
studied breast cancer antibody​—​increased phagocytosis of human breast cancer cells compared 
to anti-Her2/neu alone. This coupled treatment was tested in vivo and revealed increased 
anti-tumor responses in a mouse breast cancer model. Co-treatment illustrates the possibility for 
more “don’t-eat-me” signals present on cancer cells. Despite CV1s’ efficacy, its high affinity 
caused on-target CD47 binding across all cell types. Although this high-affinity is wanted in 
therapeutics, unwanted red blood cell phagocytosis occurred and resulted in anemia. This 
 side-effect, however, is common between all CD47 inhibitors and reverted after treatment 
(Willingham et al., 2012; Weiskopf et al., 2013). 
A solution to CD47 on-target side-effects is antagonizing SIRPα instead. CD47 is 
expressed widely across cell lines, while SIRPα is present on a subset of macrophages; therefore, 
SIRPα is arguable the favored target for cancer therapeutics (Zhao et al., 2011). One potential 
SIRPα antagonist, which showed similar potency as CV1, is Velcro-CD47- a high-affinity CD47 
variant synthesized through a novel protein “velcro” technique (Ho et al 2015). Through in vitro 
analysis, Velcro-CD47 enhanced mAb-mediated phagocytosis by inhibiting anti-phagocytic 
signals. It is important to note that the small peptide inhibitors do not, by themselves, promote 
phagocytosis. While antibodies illicit a targeted immune response, small peptides rely on the 
immune systems’ natural clearance or other cancer therapeutics to clear cancer cells. 
Other small peptide therapeutics for CD47-SIRPα inhibition include 4N1K and its 
derivative PKHB1. There has been substantial evidence that 4N1K increases PCR ​in vivo 
(​Martinez-Torres et al., 2015; Soto-Pantoja et al., 2013; Kanda et al., 1999; Kalas eat al., 2013). 
Several papers highlight a difference between CD47 +/+ and CD47 -/- tumor cells removal upon 
4N1K treatment (​Fujimoto et al., 2003)​. Unlike B6H12/Hu5F9, 4N1K is able to potentiate PCR 
of chronic lymphocytic leukemia (CLL) in soluble conditions; however, in human serum, 4N1K 
is degraded by proteases faster than antibodies-more than 90% was degraded in an 1-hour 
incubation (Martinez-Torres et al., 2015). This therapy, therefore, requires more injections for an 
accurate response. Furthermore, 4N1K has conflicting evidence for its CD47 specificity, and 
may cause off-target effects (Jeanne et al., 2015). In order to combat these issues, two terminal 
residues were replaced on 4N1K with their D analogues. This new therapeutic, PKHB1, lasted 
longer in human serum, maintained its solubility, and continued to bind CD47. PKHB1 was then 
tested ​in vivo ​and showed higher rates of CLL PCR (Martinez-Torres et al., 2015). PKHB1 is 
currently in pre-clinical trials for CLL treatment. 
 
Conclusion 
Cancer therapeutics continue to progress towards more accurate and less toxic forms. In 
turn, this eliminates the need for deleterious options like chemotherapy. CD47-SIRPα presents a 
target for future immunological therapeutics. Although anemia and off-target effects must be 
further assessed, CD47-SIRPα inhibitors present a feasible and effective option.  
CD47-SIRPα pathway is an inhibitor signal pathway that acts as a “don’t-eat-me” signal 
for healthy cells. Upon binding to CD47, SIRPα causes a signal cascade within the immune cell, 
and shifts carbon metabolism resulting in a M1 phenotype (Alvey and Discher, 2017). Cancer 
cells were shown to over express CD47 and it is believed that this alone can prevent PCR and 
allow tumor progression (Oldenborg et al., 2001; Ho et al., 2015) . However, inhibiting the 
CD47-SIRPα pathway alone did not cause an increase in tumor cell phagocytosis forcing 
co-treatments, and providing evidence for other inhibitors signals (Zhao et al., 2011; Chao et al., 
2011). 
 Anti-CD47 antibodies increase tumor cell phagocytosis in a coupled therapy with 
Rituximab and show accurate responses in Phase I clinical trials (Advani et al., 2018). However, 
CD47 is widely expressed across cell lines, and its therapeutics cause on-target healthy cell 
phagocytosis. In response to this concern, anti-SIRPα antibodies have been developed which 
illustrated similar phagocytic responses ​in vivo ​with higher cell type specificity (Zhao et al., 
2011)​. ​Regardless, blocking the CD47-SIRPα pathways still causes anemia in patients. This is an 
expected and treatable side-effect that naturally reverts after a short-term treatment. No 
long-term effects of antibody treatments have been assessed and remains a limitation to these 
studies.  
To combat the limitations seen in antibody treatments, small peptide inhibitors are being 
developed for the CD47-SIRPα pathway. While this division of therapeutics do not, by 
themselves, cause phagocytosis, they enhance treatment of known cancer drugs. Velcro-CD47 
presented a novel protein manufacturing technique and provided a high-affinity peptide to 
prevent inhibitor signals (Weiskopf et al., 2013). 4N1K has been shown to increase tumor cell 
phagocytosis between CD47 +/+ and CD47-/- but remains controversial for off-target effects 
(​Fujimoto et al., 2003; ​Jeanne et al., 2015). Despite the progress, small peptide inhibitors are 
hindered by their short half-life in blood serum due to protease activity. Further development of 
4N1K produced PKHB 1, which lasted longer in human serum, maintained its solubility, and has 
entered pre-clinical trials (Martinez-Torres et al., 2015).  
By blocking the CD47-SIRPα pathway and other inhibitor signals, researchers can trigger 
a natural immune clearance of cancer cells. Although differences between CD47 and SIRPα 
therapeutics, long-term effects, and 4N1K off-target effects must be further assessed, preliminary 
research indicates this pathway as a potential target for future therapeutics.  
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